NVTA - Invitae Corporation
10.32 -0.07 (-0.66%)
After hours: 4:11PM EDT
| Previous Close | 10.06 |
| Open | 10.06 |
| Bid | 10.30 x 900 |
| Ask | 10.79 x 1300 |
| Day's Range | 10.03 - 10.50 |
| 52 Week Range | 4.35 - 10.50 |
| Volume | 890,914 |
| Avg. Volume | 914,689 |
| Market Cap | 716.717M |
| Beta | 1.61 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.44 |
| Earnings Date | Feb 12, 2018 - Feb 16, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 12.33 |
- Motley Fool•7 days ago
Here's Why Invitae Corp Rose as Much as 20.6% Today
The genetic testing leader delivered another strong quarter of growth.
- Zacks•8 days ago
Invitae (NVTA) Reports Q2 Loss, Tops Revenue Estimates
Invitae (NVTA) delivered earnings and revenue surprises of 16.07% and 21.54%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
- Associated Press•8 days ago
Invitae: 2Q Earnings Snapshot
The San Francisco-based company said it had a loss of 47 cents per share. The results surpassed Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was ...
- PR Newswire•8 days ago
Invitae Reports More than 160% Annual Revenue Growth Driven by Nearly 140% Annual Growth in Volume in Second Quarter 2018
-- Raising annual revenue guidance amid strong quarter performance -- -- Q2 2018 gross profit of $16.9M up from $3.8M in Q2 2017 -- -- Management hosting conference call and webcast today at 4:30pm Eastern/1:30pm ...
- ACCESSWIRE•8 days ago
Invitae Corp. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / August 7, 2018 / Invitae Corp. (NYSE: NVTA ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 7, 2018 at 4:30 PM Eastern Time. To listen ...
- Zacks•9 days ago
Cerner (CERN) Looks Good: Stock Adds 6.2% in Session
Cerner (CERN) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.
- Zacks•20 days ago
Invitae (NVTA): Moving Average Crossover Alert
Invitae Corporation (NVTA) is looking like an interesting pick from a technical perspective
- PR Newswire•22 days ago
Invitae to announce second quarter 2018 Financial Results on August 7, 2018
SAN FRANCISCO, July 24, 2018 /PRNewswire/ -- Invitae Corporation (NVTA), one of the fastest growing genetics companies, today announced that it will report its second quarter 2018 financial results on Tuesday, August 7, 2018 and will host a conference call and webinar that day at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss its financial results and recent highlights. The dial-in numbers for the conference call are (866) 393-4306 for domestic callers and (734) 385-2616 for international callers, and the reservation number for both is 3497996. Invitae Corporation (NVTA) is a genetic testing and information company.
- ACCESSWIRE•last month
Free Stock Performance Review on IQVIA Holdings and Three Additional Medical Research Stocks
LONDON, UK / ACCESSWIRE / July 16, 2018 / If you want a free Stock Review on IQV sign up now at www.wallstequities.com/registration. WallStEquities.com has selected the following Medical Laboratories and Research stocks for review this morning: iKang Healthcare Group Inc. (NASDAQ: KANG), Invitae Corp. (NYSE: NVTA), IQVIA Holdings Inc. (NYSE: IQV), and Laboratory Corp. of America Holdings (NYSE: LH).
- Motley Fool•last month
Here's Why Invitae Dropped 14.9% in 2018 (So Far)
The genetic testing leader is growing at a healthy clip, but still burning through piles of cash.
- PR Newswire•2 months ago
Invitae Expands Reproductive Health Offering with Launch of Comprehensive Genetic Carrier Screening
SAN FRANCISCO, June 25, 2018 /PRNewswire/ -- Invitae Corporation (NVTA), one of the fastest growing genetics companies, today announced the launch of the Invitae Carrier Screen, a comprehensive test designed to provide affordable, accessible information on genetic changes that pose a risk for parents of having a child with an inherited genetic disorder. "By providing affordable, comprehensive, high-quality genetic information, Invitae carrier testing can help parents-to-be have the information they need to make appropriate health decisions when starting a family," said Robert Nussbaum, M.D., chief medical officer of Invitae.
- PR Newswire•2 months ago
Invitae Study of 143,000 Patients Shows Importance of Routinely Including Deletion and Duplication Detection with Sequencing in Genetic Testing
SAN FRANCISCO, June 13, 2018 /PRNewswire/ -- Researchers from Invitae, one of the fastest growing genetics companies, today published findings from the largest analysis to date of genetic testing to identify deletions and duplications involving single genes using next-generation sequencing (NGS) techniques. The study found that these changes, also called exonic copy number variants (CNVs), are present in a substantial number of patients and suggested that CNV testing should be universally used in clinical genetic testing. With few exceptions, these types of exonic CNVs are not typically detectable or reported from cytogenetic methods such as whole-genome chromosomal microarrays.
- ACCESSWIRE•2 months ago
Stock Performance Review on Exact Sciences and Three Other Medical Research Stocks
Gains were broad based as eight out of nine sectors finished the trading session in green. WallStEquities.com has initiated research reports on the following Medical Laboratories & Research stocks: DexCom Inc. (NASDAQ: DXCM), Exact Sciences Corp. (NASDAQ: EXAS), iKang Healthcare Group Inc. (NASDAQ: KANG), and Invitae Corp. (NYSE: NVTA).
- PR Newswire•3 months ago
Invitae to Present at the William Blair 2018 Growth Stock Conference
SAN FRANCISCO, May 30, 2018 /PRNewswire/ -- Invitae Corporation (NVTA), one of the fastest growing genetics companies, today announced that Sean George, co-founder and chief executive officer of Invitae, will present at the William Blair 2018 Growth Stock Conference on Tuesday, June 12, 2018 at 4:10 p.m. Central / 5:10 p.m. Eastern / 2:10 p.m. Pacific in Chicago. Invitae Corporation (NVTA) is a genetics company whose mission is to bring comprehensive genetic information into mainstream medical practice to improve the quality of healthcare for billions of people. Invitae's goal is to aggregate most of the world's genetic tests into a single service with higher quality, faster turnaround time and lower prices.
- Motley Fool•3 months ago
Why This Genetics Stock Could Be a Gold Mine for Growth Investors
Invitae reported $1.6 million in revenue in 2014. This year it expects more than $130 million.
- Thomson Reuters StreetEvents•3 months ago
Edited Transcript of NVTA earnings conference call or presentation 9-May-18 8:30pm GMT
Q1 2018 Invitae Corp Earnings Call
- Motley Fool•3 months ago
Here's Why Invitae Rose as Much as 13.9% Today
The company's first-quarter 2018 performance exceeded even its own lofty expectations.
- Associated Press•3 months ago
Invitae: 1Q Earnings Snapshot
On a per-share basis, the San Francisco-based company said it had a loss of 66 cents. The results fell short of Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment ...
- PR Newswire•3 months ago
Invitae Reports 169% Revenue Growth Driven by 150% Growth in Volume in First Quarter 2018
-- Raising annual volume and revenue guidance -- -- Q1 2018 gross profit of $9.6M up from $1.0M in Q1 2017 -- -- Management hosting conference call and webcast today at 4:30pm Eastern/1:30pm Pacific -- ...
- Zacks•3 months ago
The Zacks Analyst Blog Highlights: Audiocodes, Farmland Partners, Invitae, Global Medical and Glu
The Zacks Analyst Blog Highlights: Audiocodes, Farmland Partners, Invitae, Global Medical and Glu
- Zacks•3 months ago
5 of the Best Stocks Under $10 for 2018
Today we've highlighted five stocks that are currently trading for under $10 per share. All of these stocks currently sport a Zacks Rank #2 (Buy) or better, and the selected companies are showing signs of outpacing the market in the current calendar year.
- Zacks•3 months ago
Zacks.com featured highlights include: Del Taco, WellCare Health, Invitae, Visteon and Toll Brothers
Zacks.com featured highlights include: Del Taco, WellCare Health, Invitae, Visteon and Toll Brothers
- Zacks•3 months ago
Play Stocks With Rising P/E to Enjoy Solid Gains
Want to try an out-of-the-box approach? Tap five stocks with increasing P/E ratios.
- PR Newswire•3 months ago
Sarepta and Invitae Expand Partnership to Advance Clinical Research in Duchenne Muscular Dystrophy
"Our partnership with Invitae is important to advancing our clinical study objectives across our entire RNA-based platform," said Doug Ingram, Sarepta's President and CEO. DMD is a rare, fatal neuromuscular genetic disease that occurs in approximately one in every 3,500 – 5,000 males worldwide and is caused by a change or mutation in the gene that encodes instructions for dystrophin.
